通过激活JAK/STAT3信号通路,RAB32促进质瘤细胞的进展
Sinan Zhang1,2, Xudong Jiang2,3, Qing Wei1
1Jiamusi University, Jiamusi, Heilongjiang, China.
The Journal of international medical research
|December 4, 2024
概括
通过激活JAK/STAT3通路,RAB32蛋白促进质母细胞瘤的生长和扩散. 抑制RAB32为质母细胞瘤治疗提供了潜在的新疗法策略.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症信号传递 癌症信号传递
背景情况:
- 质母细胞瘤 (GBM) 是一种具有有限治疗选择的侵袭性脑瘤.
- 了解GBM进展的分子驱动因素对于开发有效疗法至关重要.
研究的目的:
- 为了研究RAB32在质母细胞瘤中的作用.
- 阐明RAB32影响质瘤进展的分子机制.
主要方法:
- 通过生物信息学数据库和西部抹杀,评估了RAB32表达和预后价值.
- 在体外研究中操纵了质瘤细胞中的RAB32水平,以评估对增殖,迁移和入侵的影响.
- 通过基因组丰富分析和抑制剂研究,分析了JAK/STAT3信号通路的参与.
主要成果:
- 在质瘤患者和细胞系中,RAB32表达显著上调,与瘤等级呈正相关性.
- RAB32作为质瘤的独立预后因素.
- 抑制RAB32抑制了质母细胞细胞的增殖,迁移和入侵,而过度表达具有相反的效果,由JAK/STAT3抑制剂逆转.
结论:
- RAB32通过JAK/STAT信号通路促进质母细胞瘤细胞恶性瘤.
- RAB32代表了质母细胞瘤的潜在治疗点.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K


